Studybox Research 510(k) Clinical Studies
Influenza A/B Rapid Antigen Test
Clinical and analytical performance to support substantial equivalence.
Studybox
510(k) Clinical Studies
Antigen-based rapid influenza diagnostic tests were reclassified into Class II with special controls after years of concern about low sensitivity. The special controls set minimum clinical performance that antigen tests must meet against a molecular comparator or viral culture, and require annual analytical reactivity testing against contemporary circulating strains. A clinical study for a new or modified rapid influenza antigen test is designed with those thresholds in mind from the first draft of the protocol.
The study enrolls patients with influenza-like illness during the respiratory season at urgent care centers, physician offices and other point-of-care sites. Each subject contributes a device specimen and a comparator specimen, and the analysis is run separately for influenza A and influenza B. Influenza B is routinely the limiting analyte because it circulates at lower levels in most seasons, and a study that comfortably meets its influenza A target can fall short on B.
- Analyte
- Influenza A and influenza B nucleoprotein antigens
- Therapeutic area
- Infectious Disease
- Specimens
- Nasopharyngeal (NP) Swab, Anterior Nares (Nasal) Swab
- Intended-use settings
- urgent care, physician office, pharmacy, hospital POC, emergency department
- Operators
- Medical assistants, nurses and other non-laboratory clinic staff in CLIA-waived settings; laboratory personnel for moderate-complexity 510(k)-only claims.
- Comparator
- Typically an FDA-cleared influenza A/B RT-PCR assay on a paired specimen; viral culture is the historical alternative and remains an accepted comparator under the special controls.
510(k) Studies specifics
What Changes for This Assay on This Pathway.
- The special controls set minimum positive and negative percent agreement for antigen tests against a cleared molecular comparator or viral culture; the protocol should pre-specify which comparator type is used, and reviewers assess the confidence interval, not only the point estimate.
- Annual reactivity testing against contemporary strains is an ongoing obligation under the special controls and is typically described in the 510(k) alongside the clinical data.
- Prospective fresh specimens from the current season are expected; archived frozen specimens, if used to reach enough influenza B positives, are typically analyzed and reported separately.
Endpoints the study must support
- Positive and negative percent agreement for influenza A and for influenza B separately against the molecular comparator, each with two-sided 95% confidence intervals
- Performance stratified by specimen type, age group and days since symptom onset
- Invalid result rate and, for visually read devices, inter-reader agreement
Enrollment realities
Sample size is driven by the number of influenza B positives needed for a lower confidence bound above the special-control threshold; in a mild or A-dominant season this can double planned enrollment. Enrollment concentrates in the weeks of peak circulation, so sites must be active before the season begins. Northern Hemisphere influenza season, typically late fall through early spring, with influenza B often peaking later than influenza A.
How Studybox runs it
Pre-Qualified Sites, Embedded Coordinators.
Our 100+ pre-qualified U.S. sites are matched to the intended-use population and setting, with Studybox coordinators embedded on site for recruitment, consent, specimen handling, and data capture. Typical activation is about four weeks. How we run 510(k) clinical studies →
Same assay, other pathways
Relevant FDA guidance
- Establishing the Performance Characteristics of In Vitro Diagnostic Devices for the Detection or Detection and Differentiation of Influenza Viruses
- Recommendations for Dual 510(k) and CLIA Waiver by Application Studies
- Recommendations for Clinical Laboratory Improvement Amendments of 1988 (CLIA) Waiver Applications for Manufacturers of In Vitro Diagnostic Devices
- Statistical Guidance on Reporting Results from Studies Evaluating Diagnostic Tests
FAQ
Influenza A/B Rapid Antigen Test Study Questions.
01 Who operates the influenza a/b rapid antigen test in a 510(k) studies study?
Medical assistants, nurses and other non-laboratory clinic staff in CLIA-waived settings; laboratory personnel for moderate-complexity 510(k)-only claims.
02 What is the comparator for a influenza a/b rapid antigen test study?
Typically an FDA-cleared influenza A/B RT-PCR assay on a paired specimen; viral culture is the historical alternative and remains an accepted comparator under the special controls.
03 What drives enrollment for a influenza a/b rapid antigen test study?
Sample size is driven by the number of influenza B positives needed for a lower confidence bound above the special-control threshold; in a mild or A-dominant season this can double planned enrollment. Enrollment concentrates in the weeks of peak circulation, so sites must be active before the season begins. Northern Hemisphere influenza season, typically late fall through early spring, with influenza B often peaking later than influenza A.
Let's talk IVD research
Planning a influenza a/b rapid antigen test study?
Tell us the intended use and setting. We'll come back with a site plan, operator strategy, and a realistic activation timeline for the 510(k) studies pathway.